UT MD Anderson Cancer Center 
Welcome,         Profile    Billing    Logout  
 31 Products   13 Diseases  31 Products   34 Trials   1903 News 
40 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
CXCR2 and NGFR transduced TIL / UT MD Anderson Cancer Center
NCI-2014-02655, NCT01740557: Genetically Modified Therapeutic Autologous Lymphocytes Followed by Aldesleukin in Treating Patients With Stage III or Metastatic Melanoma

Completed
1/2
10
US
Aldesleukin, 125-L-Serine-2-133-interleukin 2, Proleukin, r-serHuIL-2, Recombinant Human IL-2, Recombinant Human Interleukin-2, CXCR2-transduced Autologous Tumor Infiltrating Lymphocytes, CXCR2-transduced Autologous TILs, Cyclophosphamide, (-)-Cyclophosphamide, 2H-1,3,2-Oxazaphosphorine, 2-[bis(2-chloroethyl)amino]tetrahydro-, 2-oxide, monohydrate, Carloxan, Ciclofosfamida, Ciclofosfamide, Cicloxal, Clafen, Claphene, CP monohydrate, CTX, CYCLO-cell, Cycloblastin, Cycloblastine, Cyclophospham, Cyclophosphamid monohydrate, Cyclophosphamidum, Cyclophosphan, Cyclophosphane, Cyclophosphanum, Cyclostin, Cyclostine, Cytophosphan, Cytophosphane, Cytoxan, Fosfaseron, Genoxal, Genuxal, Ledoxina, Mitoxan, Neosar, Revimmune, Syklofosfamid, WR- 138719, Fludarabine Phosphate, 2-F-ara-AMP, 9H-Purin-6-amine, 2-fluoro-9-(5-O-phosphono-.beta.-D-arabinofuranosyl)-, Beneflur, Fludara, SH T 586, Laboratory Biomarker Analysis, NGFR-transduced Autologous T Lymphocytes, Quality-of-Life Assessment, Quality of Life Assessment
M.D. Anderson Cancer Center, National Cancer Institute (NCI)
Metastatic Melanoma, Stage III Cutaneous Melanoma AJCC v7, Stage IV Cutaneous Melanoma AJCC v6 and v7
04/23
04/23
nelitolimod (SD-101) / TriSalus Life Sci, UT MD Anderson Cancer Center
NCT03007732: Pembrolizumab +/- SD-101 in Hormone-Naïve Oligometastatic Prostate Cancer With RT and iADT

Active, not recruiting
2
23
US
Pembrolizumab, MK-3475, Keytruda, SD-101, Toll-like receptor 9, Leuprolide acetate, Intermittent androgen deprivation therapy, Abiraterone Acetate, Prednisone, Stereotactic Body Radiation Therapy, SBRT
David Oh, Prostate Cancer Foundation, Merck Sharp & Dohme LLC, TriSalus Life Sciences, Inc.
Prostatic Neoplasms
08/25
08/25
I-SPY 2, NCT01042379: I-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast Cancer

Hourglass Jan 2023 - Dec 2023 : From P2 I-SPY 2 trial for invasive breast cancer
Checkmark Presentation of data from I-SPY trial for HR+/HER2- and TNBC breast cancer at SABCS 2022
Dec 2022 - Dec 2022: Presentation of data from I-SPY trial for HR+/HER2- and TNBC breast cancer at SABCS 2022
Checkmark Data from trial evaluating T-DM1+pertuzumab in the adjuvant setting
Nov 2018 - Nov 2018: Data from trial evaluating T-DM1+pertuzumab in the adjuvant setting
More
Recruiting
2
5000
US
Standard Therapy, Paclitaxel (Taxol); Doxorubicin (Adriamycin), AMG 386 with or without Trastuzumab, AMG 386 (Trebananib); (Trastuzumab) Herceptin, AMG 479 (Ganitumab) plus Metformin, Ganitumab, MK-2206 with or without Trastuzumab, (Trastuzumab) Herceptin, AMG 386 and Trastuzumab, AMG 386 (Trebananib); Trastuzumab (Herceptin), T-DM1 and Pertuzumab, T-DM1 (Trastuzumab emtansine); Pertuzumab (Perjeta), Pertuzumab and Trastuzumab, Pertuzumab (Perjeta); Trastuzumab (Herceptin), Ganetespib, ABT-888, Veliparib, Neratinib, PLX3397, Pembrolizumab - 4 cycle, Talazoparib plus Irinotecan, Patritumab and Trastuzumab, Pembrolizumab - 8 cycle, SGN-LIV1A, Durvalumab plus Olaparib, SD-101 + Pembrolizumab, Tucatinib plus trastuzumab and pertuzumab, Cemiplimab, Cemiplimab plus REGN3767, Trilaciclib with or without trastuzumab + pertuzumab, Trilaciclib (G1T28); Pertuzumab (Perjeta); Trastuzumab (Herceptin), SYD985 ([vic-]trastuzumab duocarmazine), Oral Paclitaxel + Encequidar + Dostarlimab (TSR-042) + Carboplatin with or without trastuzumab, Oral Paclitaxel + Encequidar (Oraxol); Dostarlimab (TSR-042); Trastuzumab (Herceptin), Oral Paclitaxel + Encequidar + Dostarlimab (TSR-042) with or without trastuzumab, Amcenestrant, SAR439859, Amcenestrant + Abemaciclib, Amcenestrant (SAR439859), Abemaciclib (Verzenio), Amcenestrant + Letrozole, Amcenestrant (SAR439859), Letrozole (Femara), ARX788, ARX788 + Cemiplimab, VV1 + Cemiplimab, VOYAGER V1™, VSV-IFNβ-NIS, Datopotamab deruxtecan, Dato-DXd, Datopotamab deruxtecan + Durvalumab, Zanidatamab, Lasofoxifene, Z-endoxifen, ARV-471, ARV-471 + Letrozole, ARV-471 + Abemaciclib, Endoxifen + Abemaciclib, Rilvegostomig + TDXd, Dan222 + Niraparib, Sarilumab + Cemiplimab + Paclitaxel
QuantumLeap Healthcare Collaborative
Breast Neoplasms, Breast Cancer, Breast Tumors, Angiosarcoma, TNBC - Triple-Negative Breast Cancer, HER2-positive Breast Cancer, HER2-negative Breast Cancer, Hormone Receptor Positive Tumor, Hormone Receptor Negative Tumor, Early-stage Breast Cancer, Locally Advanced Breast Cancer
12/30
12/31
NCT02927964: TLR9 Agonist SD-101, Ibrutinib, and Radiation Therapy in Treating Patients With Relapsed or Refractory Grade 1-3A Follicular Lymphoma

Completed
1/2
21
US
Ibrutinib, BTK Inhibitor PCI-32765, CRA-032765, PCI-32765, Radiation Therapy, Cancer Radiotherapy, Irradiate, Irradiated, Irradiation, RADIATION, Radiotherapeutics, Radiotherapy, RT, Therapy, Radiation, TLR9 Agonist SD-101, ISS-ODN SD-101, SD-101
Robert Lowsky, Janssen, LP, National Cancer Institute (NCI), The Leukemia and Lymphoma Society, Rising Tide Foundation
Grade 1 Follicular Lymphoma, Grade 2 Follicular Lymphoma, Grade 3a Follicular Lymphoma, Recurrent Follicular Lymphoma, Refractory Follicular Lymphoma, Mantle Cell Lymphoma, Marginal Zone Lymphoma
05/23
05/23
PERIO-02, NCT05220722: Pressure Enabled Delivery of SD-101 With Checkpoint Blockade for Primary Liver Tumors

Active, not recruiting
1/2
89
US
SD-101, Pembrolizumab, Keytruda, Nivolumab, Opdivo, Ipilimumab, Yervoy
TriSalus Life Sciences, Inc.
Hepatocellular Carcinoma, Intrahepatic Cholangiocarcinoma
12/23
01/25
NCT03831295: SD-101 and BMS-986178 in Treating Patients With Advanced or Metastatic Solid Malignancies

Completed
1
12
US
Anti-OX40 Antibody BMS 986178, BMS 986178, BMS-986178, TLR9 Agonist SD-101, ISS-ODN SD-101, SD-101
Ronald Levy, Bristol-Myers Squibb
Advanced Malignant Solid Neoplasm, Extracranial Solid Neoplasm, Metastatic Malignant Solid Neoplasm
10/21
10/21
NCT04050085: SD-101, Nivolumab, and Radiation Therapy in Treating Patients With Chemotherapy-Refractory Metastatic Pancreatic Cancer

Completed
1
6
US
Nivolumab, BMS-936558, MDX-1106, NIVO, ONO-4538, Opdivo, Radiation Therapy, Cancer Radiotherapy, Irradiate, Irradiated, irradiation, Radiation, Radiotherapeutics, RADIOTHERAPY, RT, Therapy, Radiation, TLR9 Agonist SD-101, ISS-ODN SD-101, SD-101
University of California, Davis, National Cancer Institute (NCI), Bristol-Myers Squibb, Dynavax Technologies Corporation
Metastatic Pancreatic Adenocarcinoma, Refractory Pancreatic Adenocarcinoma, Stage IV Pancreatic Cancer AJCC v8
12/21
05/22
NCT03410901: TLR9 Agonist SD-101, Anti-OX40 Antibody BMS 986178, and Radiation Therapy in Treating Patients With Low-Grade B-Cell Non-Hodgkin Lymphomas

Completed
1
14
US
Anti-OX40 Antibody BMS 986178, BMS 986178, BMS-986178, Laboratory Biomarker Analysis, Radiation Therapy, Cancer Radiotherapy, Irradiate, Irradiated, irradiation, RADIATION, Radiotherapeutics, radiotherapy, RT, Therapy, Radiation, TLR9 Agonist SD-101, ISS-ODN SD-101, SD-101
Ronald Levy, National Cancer Institute (NCI)
B-Cell Non-Hodgkin Lymphoma, Grade 1 Follicular Lymphoma, Grade 2 Follicular Lymphoma, Grade 3a Follicular Lymphoma, Lymphoplasmacytic Lymphoma, Mantle Cell Lymphoma, Marginal Zone Lymphoma, Small Lymphocytic Lymphoma
10/24
10/24
PERIO-01, NCT04935229: Intrahepatic Delivery of SD-101 by Pressure-Enabled Regional Immuno-oncology (PERIO), With Checkpoint Blockade in Adults With Metastatic Uveal Melanoma

Hourglass Jul 2024 - Dec 2024 : P1 data from PERIO-01 trial for uveal melanoma liver metastases
Active, not recruiting
1
80
US
SD-101, Nivolumab, Opdivo, Ipilimumab, Yervoy, Nivolumab and Relatlimab, Opdualag
TriSalus Life Sciences, Inc.
Metastatic Uveal Melanoma in the Liver
09/24
01/25
PERIO-03, NCT05607953: Pressure Enabled Intrapancreatic Delivery of SD-101 With Checkpoint Blockade for Locally Advanced Pancreatic Adenocarcinoma

Recruiting
1
60
US
SD-101, anti-PD-1
TriSalus Life Sciences, Inc.
Locally Advanced Pancreatic Adenocarcinoma
10/24
10/26
NCT06710223: Cryoablation and Arterial Infusion of SD-101 in Combination with Durvalumab and Tremelimumab

Recruiting
1
20
US
SD-101, nelitolimod, Cryotherapy, Tremelimumab, Durvalumab
University of California, San Diego, TriSalus Life Sciences
Hepatocellular Carcinoma
06/27
06/27
UCART123 / Cellectis
2018-001018-14: Study to evaluate the safety and efficacy of UCART123 in adults with high risk Acute Myeloid Leukaemia

Not yet recruiting
1/2
18
Europe
UCART123, Infusion
CELLECTIS SA, CELLECTIS SA
Adverse genetic Acute Myeloid Leukaemia, Blood Cancer, Diseases [C] - Cancer [C04]
 
 
AMELI-01, NCT03190278: Study Evaluating Safety and Efficacy of UCART123v1.2 in Patients With Relapsed/Refractory Acute Myeloid Leukemia

Hourglass Jan 2021 - Dec 2021 : Data from trial for r/r AML
Hourglass Jun 2021 - Jun 2021 : Mature data from trial for r/r AML at ASCO/EHA 2021
Checkmark Initiated AMELI-01 trial for r/r AML
Jan 2020 - Jan 2020: Initiated AMELI-01 trial for r/r AML
Recruiting
1
65
US
UCART123v1.2
Cellectis S.A.
Relapsed/Refractory Acute Myeloid Leukemia
12/24
12/24
UCART CS1 / Cellectis
MELANI-01, NCT04142619: Study Evaluating Safety and Efficacy of UCART Targeting CS1 in Patients With Relapsed/Refractory Multiple Myeloma

Terminated
1
11
US
UCARTCS1A
Cellectis S.A.
Relapsed/Refractory Multiple Myeloma
06/23
06/23
UCART22 / Cellectis
2020-004768-24: Study to evaluate the safety and efficacy of UCART22 in patients with Acute Lymphoblastic Leukaemia that have relapsed or not responded to other treatments

Not yet recruiting
1/2
83
Europe
UCART22, Infusion
CELLECTIS SA, CELLECTIS SA
Acute Lymphoblastic Leukaemia. Leucémie aiguë lymphoblastique., Blood Cancer. Leucemie., Diseases [C] - Cancer [C04]
 
 
BALLI-01, NCT04150497: Phase 1/2 Study of UCART22 in Patients With Relapsed or Refractory CD22+ B-cell Acute Lymphoblastic Leukemia

Recruiting
1/2
40
Europe, US
UCART22, CLLS52, Alemtuzumab
Cellectis S.A.
B-cell Acute Lymphoblastic Leukemia
01/26
01/26
ERAS-007 / Erasca
HERKULES-1, NCT04866134: A Study of ERAS-007 as Monotherapy or in Combination With ERAS-601 in Patients With Advanced or Metastatic Solid Tumors

Active, not recruiting
1/2
200
US
ERAS-007, ERAS-601
Erasca, Inc.
Advanced or Metastatic Solid Tumors
05/25
11/25
HERKULES-3, NCT05039177: A Study of ERAS-007 in Patients With Advanced Gastrointestinal Malignancies

Active, not recruiting
1/2
102
US
ERAS-007, Encorafenib, Braftovi, Cetuximab, Erbitux, Palbociclib, Ibrance
Erasca, Inc.
Metastatic Colorectal Cancer, Metastatic Pancreatic Ductal Adenocarcinoma
08/25
12/25
HERKULES-2, NCT04959981: A Study of Anti-Cancer Therapies Targeting the MAPK Pathway in Patients With Advanced NSCLC

Completed
1b
24
US
ERAS-007, ERAS-601, Osimertinib, Tagrisso, Sotorasib, Lumakras
Erasca, Inc.
Advanced Non-squamous Non-small-cell Lung Cancer
04/23
04/23
vibecotamab (XmAb14045) / Xencor
NCI-2022-02215, NCT05285813: A Phase II Study of Vibecotamab (XmAb14045) for MRD- Positive AML and MDS After Hypomethylating Agent Failure

Recruiting
2
42
US
Vibecotamab, XmAb14045, Dexamethasone, Decadron, Acetaminophen, Tylenol®, Dorcol®, Feverallâ"¢, Panadol®, APAP, N-Acetyl-P-Aminophenol, Paracetamol, Ofirmevâ"¢, Diphenhydramine, Benadryl®
M.D. Anderson Cancer Center
AML, MDS
12/26
12/26
MDA-TIL / Iovance Biotherap, UT MD Anderson Cancer Center
NCI-2018-01509, NCT03610490: Autologous Tumor Infiltrating Lymphocytes MDA-TIL in Treating Patients With Recurrent or Refractory Ovarian Cancer, Colorectal Cancer, or Pancreatic Ductal Adenocarcinoma

Terminated
2
60
US
Autologous Tumor Infiltrating Lymphocytes MDA-TIL, MDA Autologous TILs, MDA Autologous Tumor Infiltrating Lymphocytes, MDA-TILs, Cyclophosphamide, (-)-Cyclophosphamide, 2H-1,3,2-Oxazaphosphorine, 2-[bis(2-chloroethyl)amino]tetrahydro-, 2-oxide, monohydrate, Carloxan, Ciclofosfamida, Ciclofosfamide, Cicloxal, Clafen, Claphene, CP monohydrate, CTX, CYCLO-cell, Cycloblastin, Cycloblastine, Cyclophospham, Cyclophosphamid monohydrate, Cyclophosphamide Monohydrate, Cyclophosphamidum, Cyclophosphan, Cyclophosphane, Cyclophosphanum, Cyclostin, Cyclostine, Cytophosphan, Cytophosphane, Cytoxan, Fosfaseron, Genoxal, Genuxal, Ledoxina, Mitoxan, Neosar, Revimmune, Syklofosfamid, WR- 138719, Fludarabine, Fluradosa, Interleukin-2, Epidermal Thymocyte Activating Factor, ETAF, IL-2, IL2, IL2 Protein, Interleukin 2, Interleukin 2 Precursor, Interleukin II, Lymphocyte Mitogenic Factor, Mitogenic Factor, Ro-236019, T Cell Growth Factor, T-Cell Growth Factor, TCGF, Thymocyte Stimulating Factor, TSF, Quality-of-Life Assessment, Quality of Life Assessment
M.D. Anderson Cancer Center, Bristol-Myers Squibb, Iovance Biotherapeutics, National Cancer Institute (NCI)
Malignant Solid Neoplasm, Metastatic Colorectal Adenocarcinoma, Metastatic Ovarian Carcinoma, Metastatic Pancreatic Ductal Adenocarcinoma, Platinum-Resistant Ovarian Carcinoma, Recurrent High Grade Ovarian Serous Adenocarcinoma, Recurrent Ovarian Carcinosarcoma, Refractory Colorectal Carcinoma, Stage IV Colorectal Cancer AJCC v8, Stage IVA Colorectal Cancer AJCC v8, Stage IVB Colorectal Cancer AJCC v8, Stage IVC Colorectal Cancer AJCC v8
08/24
08/24
RPM CD19-mbIL15-CAR-T cells / Alaunos Therap, UT MD Anderson Cancer Center, Eden BioCell
ChiCTR2000034793: An Exploratory Clinical Study Evaluating the Safety and Efficacy of Anti-CD19 Autologous CAR T-cells Produced by Rapid Personalized Manufacture (RPM CD19-mbIL15-CAR-T Cell Infusion) in Patients With Relapsed/Refractory B-cell Malignancies

Not yet recruiting
N/A
12
 
RPM CD19-mbIL15-CAR-T cell infusion
Ningbo First Hospital; TriArm Therapeutics (Shanghai) Co., Ltd, TriArm Therapeutics (Shanghai) Co., Ltd
B cell malignancy
 
 
ChiCTR2100050678: An Exploratory Clinical Study Evaluating the Safety and Efficacy of Anti-CD19 Autologous CAR T-cells Produced by Rapid Personalized Manufacture (RPM CD19-mbIL15-CAR-T Cell Infusion) in Patients With Relapsed/Refractory B-cell Malignancies

Recruiting
N/A
12
 
Treat with RPM CD19-mbIL15-CAR-T cells
Tongji Hospital of Tongji University; TriArm Therapeutics (shanghai) Co., Ltd., TriArm Therapeutics (Shanghai) Co., Ltd
B cell malignancy
 
 
NTRX-07 / NeuroTherapia
NCT06194552: A Multiple Dose Study of the Safety and Pharmacokinetics of NTRX-07

Completed
1
32
Europe, US
NTRX-07, MDA7, Placebo
NeuroTherapia, Inc., CRU Early Phase Unit Kistarcsa
Alzheimer Disease
05/23
06/23
KA2507 / Karus Therap, UT MD Anderson Cancer Center
2019-001459-38: Finding the tolerable recommended dose of KA2507 and how effective it is at treating patient with advance biliary tract cancer who have previously been treated with standard of care chemotherapy

Not yet recruiting
2
40
Europe
KA2507, N/A, Capsule, hard
Karus Therapeutics Limited
Advanced Biliary Tract Cancer, Advanced Biliary Tract cancer, Diseases [C] - Cancer [C04]
 
 
JIN-001 / J Ints Bio
MPT0B64, NCT04294875: Phase I, FIH, MTD for 0, Multi-centre, Open-label, Subject With Locally Advanced or Metastatic Solid Malignancies

Withdrawn
1
15
NA
MPT0B640
J Ints Bio
Advanced Solid Tumor, Metastatic Solid Tumor
11/27
11/27
IPN60090 / UT MD Anderson Cancer Center, Ipsen
NCT05039801: IACS-6274 With or Without Bevacizumab and Paclitaxel for the Treatment of Advanced Solid Tumors

Recruiting
1
54
US
Bevacizumab, ABP 215, Anti-VEGF, Anti-VEGF Humanized Monoclonal Antibody, Anti-VEGF Monoclonal Antibody SIBP04, Anti-VEGF rhuMAb, Avastin, Bevacizumab awwb, Bevacizumab Biosimilar ABP 215, Bevacizumab Biosimilar BEVZ92, Bevacizumab Biosimilar BI 695502, Bevacizumab Biosimilar CBT 124, Bevacizumab Biosimilar CT-P16, Bevacizumab Biosimilar FKB238, Bevacizumab Biosimilar GB-222, Bevacizumab Biosimilar HD204, Bevacizumab Biosimilar HLX04, Bevacizumab Biosimilar IBI305, Bevacizumab Biosimilar LY01008, Bevacizumab Biosimilar MIL60, Bevacizumab Biosimilar Mvasi, Bevacizumab Biosimilar MYL-1402O, Bevacizumab Biosimilar QL 1101, Bevacizumab Biosimilar QL1101, Bevacizumab Biosimilar RPH-001, Bevacizumab Biosimilar SCT501, Bevacizumab Biosimilar Zirabev, Bevacizumab-awwb, Bevacizumab-bvzr, BP102, BP102 Biosimilar, HD204, Immunoglobulin G1 (Human-Mouse Monoclonal rhuMab-VEGF Gamma-Chain Anti-Human Vascular Endothelial Growth Factor), Disulfide With Human-Mouse Monoclonal rhuMab-VEGF Light Chain, Dimer, Mvasi, MYL-1402O, QL1101, Recombinant Humanized Anti-VEGF Monoclonal Antibody, rhuMab-VEGF, SCT501, SIBP 04, SIBP-04, SIBP04, Zirabev, Glutaminase-1 Inhibitor IACS-6274, GLS1 Inhibitor IACS-6274, IACS 6274, IACS-6274, IACS6274, IPN 60090, IPN-60090, IPN60090, Paclitaxel, Anzatax, Asotax, Bristaxol, Praxel, Taxol, Taxol Konzentrat, Capivasertib, AZD5363
M.D. Anderson Cancer Center
Advanced Endometrial Carcinoma, Advanced Head and Neck Squamous Cell Carcinoma, Advanced Malignant Solid Neoplasm, Advanced Melanoma, Advanced Ovarian Clear Cell Adenocarcinoma, Chondrosarcoma, Clinical Stage III Cutaneous Melanoma AJCC v8, Clinical Stage IV Cutaneous Melanoma AJCC v8, Pathologic Stage III Cutaneous Melanoma AJCC v8, Pathologic Stage IIIA Cutaneous Melanoma AJCC v8, Pathologic Stage IIIB Cutaneous Melanoma AJCC v8, Pathologic Stage IIIC Cutaneous Melanoma AJCC v8, Pathologic Stage IIID Cutaneous Melanoma AJCC v8, Pathologic Stage IV Cutaneous Melanoma AJCC v8, Recurrent Ovarian High Grade Serous Adenocarcinoma, Refractory Endometrial Carcinoma, Refractory Head and Neck Squamous Cell Carcinoma, Refractory Melanoma, Refractory Ovarian Clear Cell Adenocarcinoma, Refractory Ovarian High Grade Serous Adenocarcinoma, Stage III Ovarian Cancer AJCC v8, Stage III Uterine Corpus Cancer AJCC v8, Stage IIIA Ovarian Cancer AJCC v8, Stage IIIA Uterine Corpus Cancer AJCC v8, Stage IIIA1 Ovarian Cancer AJCC v8, Stage IIIA2 Ovarian Cancer AJCC v8, Stage IIIB Ovarian Cancer AJCC v8, Stage IIIB Uterine Corpus Cancer AJCC v8, Stage IIIC Ovarian Cancer AJCC v8, Stage IIIC Uterine Corpus Cancer AJCC v8, Stage IIIC1 Uterine Corpus Cancer AJCC v8, Stage IIIC2 Uterine Corpus Cancer AJCC v8, Stage IV Ovarian Cancer AJCC v8, Stage IV Uterine Corpus Cancer AJCC v8, Stage IVA Ovarian Cancer AJCC v8, Stage IVA Uterine Corpus Cancer AJCC v8, Stage IVB Ovarian Cancer AJCC v8, Stage IVB Uterine Corpus Cancer AJCC v8
05/26
05/26
TAK-007 / Takeda, UT MD Anderson Cancer Center
TAK-007-2001, NCT05020015: A Study of TAK-007 in Adults With Relapsed or Refractory (r/r) B-cell Non-Hodgkin Lymphoma (NHL)

Active, not recruiting
2
27
US
TAK-007, Chemotherapy Agents
Takeda
Relapsed or Refractory (r/r) B-cell Non-Hodgkin Lymphoma (NHL)
10/25
06/30
NCT06377228: A Study of TAK-007 in Adults With Refractory Lupus Nephritis (LN)

Not yet recruiting
1
20
NA
TAK-007, Chemotherapy Agents
Takeda
Refractory Lupus Nephritis
04/29
04/29
OBX-115 / Obsidian, UT MD Anderson Cancer Center
Agni-01, NCT06060613: Safety and Efficacy of OBX-115 in Advanced Solid Tumors

Recruiting
1/2
52
US
OBX-115
Obsidian Therapeutics, Inc.
Tumor Skin, Metastatic Melanoma, Melanoma, Lung Cancer, Metastatic Lung Cancer, Non Small Cell Lung Cancer, Metastatic Non Small Cell Lung Cancer
10/25
10/27
NCT05470283: Phase I, Open-Label, Study of Tumor Infiltrating Lymphocytes Engineered With Membrane Bound IL15 Plus Acetazolamide in Adult Patients With Metastatic Melanoma

Active, not recruiting
1
21
US
OBX-115, Acetazolamide, Cyclophosphamide, Cytoxan®, Neosar, Furosemide, Mesna, Fludarabine Phosphate, Fludarabine, Fludara
M.D. Anderson Cancer Center
Tumor, Metastatic Melanoma, Melanoma
04/27
04/27
ERAS-601 / Erasca
FLAGSHP-1, NCT04670679: A Dose Escalation/Expansion Study of ERAS-601 in Patients With Advanced or Metastatic Solid Tumors

Active, not recruiting
1
200
US, RoW
ERAS-601, Cetuximab, Erbitux, Pembrolizumab, Keytruda
Erasca, Inc.
Advanced or Metastatic Solid Tumors
11/25
02/26
BLU-222 / Blueprint Medicines
VELA, NCT05252416: () Study of BLU-222 in Advanced Solid Tumors

Hourglass Jan 2023 - Jun 2023 : Anticipated results from VELA study for BLU-222 in CDK2-vulnerable cancers
Hourglass Jan 2023 - Jun 2023 : Initial clinical data from VELA trial in CDK2-vulnerable cancers
Hourglass Jun 2023 - Jun 2023 : Safety and efficacy data from VELA trial in breast cancer and other cancers vulnerable to CDK2 inhibition
Active, not recruiting
1/2
366
Europe, US
BLU-222, Carboplatin, Ribociclib, Fulvestrant
Blueprint Medicines Corporation
Advanced Solid Tumors, HR+ Breast Cancer, CCNE1 Amplification, HER2-negative Breast Cancer, Ovarian Cancer, Endometrial Cancer, Gastric Cancer, Esophageal Adenocarcinoma, Carcinosarcoma
11/25
09/26
CB-NK-TGF-βR2-/NR3C1 / UT MD Anderson Cancer Center
NCT05040568: A PHASE IB STUDY OF IMMUNOTHERAPY WITH EX VIVO PRE-ACTIVATED AND EXPANDED CB-NK CELLS IN COMBINATION WITH CETUXIMAB, IN COLORECTAL CANCER PATIENTS WITH MINIMAL RESIDUAL DISEASE (MRD)

Active, not recruiting
1
15
US
Cetuximab, C225, Erbituxâ"¢, IMC-C225, MOAB C225, Expanded CB-NK cells, Fludarabine phosphate, Fludarabine, Fludara®, Cyclophosphamide, Cytoxan®, Neosar®
M.D. Anderson Cancer Center
Colon Cancer, Resected Stage
02/27
02/27
Undisclosed MSC-derived Exosomes with KrasG12D siRNA / UT MD Anderson Cancer Center
iEXPLORE, NCT03608631: IExosomes in Treating Participants with Metastatic Pancreas Cancer with KrasG12D Mutation

Active, not recruiting
1
15
US
Mesenchymal Stromal Cells-derived Exosomes with KRAS G12D siRNA, MSC-derived Exosomes with KrasG12D siRNA (SY); KrasG12D siRNA-loaded Mesenchymal Stromal Cells-derived Exosomes (SY)
M.D. Anderson Cancer Center
KRAS NP_004976.2:p.G12D, Metastatic Pancreatic Adenocarcinoma, Pancreatic Ductal Adenocarcinoma, Stage IV Pancreatic Cancer AJCC V8
04/25
04/25
CAR.70/IL15-transduced CB-NK cells / UT MD Anderson Cancer Center
NCT05703854: Study of CAR.70-engineered IL15-transduced Cord Blood-derived NK Cells in Conjunction With Lymphodepleting Chemotherapy for the Management of Advanced Renal Cell Carcinoma, Mesothelioma and Osteosarcoma

Recruiting
1/2
50
US
CAR.70/IL15-transduced CB-derived NK cells, Fludarabine phosphate, Fludarabine, Fludara®, Cyclophosphamide, Cytoxan®, Neosar®
M.D. Anderson Cancer Center
Advanced Renal Cell Carcinoma, Advanced Mesothelioma, Advanced Osteosarcoma
09/25
09/27
NCT05092451: Phase I/II Study of CAR.70- Engineered IL15-transduced Cord Blood-derived NK Cells in Conjunction With Lymphodepleting Chemotherapy for the Management of Relapse/Refractory Hematological Malignances

Recruiting
1/2
80
US
Cyclophosphamide, Cytoxan®, Neosar®, CAR.70/IL15-transduced CB-NK cells, Fludarabine phosphate, Fludarabine, Fludara®
M.D. Anderson Cancer Center
B-Cell Lymphoma, Myelodysplastic Syndromes (MDS), Acute Myeloid Leukemia (AML), Multiple Myeloma, Plasma Cell Leukemia, Hodgkin Lymphoma, T-cell Non-Hodgkin's Lymphoma/ T-cell Acute Lymphoblastic Leukmeia, Myelodysplastic Syndrome / Chronic Myelomonocytic Leukemia, Blastic Transformation of Chronic Myeloid Leukemia, Germ Cell Tumors
08/26
08/26
attIL2-T / UT MD Anderson Cancer Center
NCT05621668: A First-In-Human Phase 1 Trial of T-Cell Membrane-Anchored Tumor Targeted Il12 (Attil12)- T-Cell Therapy in Subjects With Advanced/Metastatic Soft Tissue and Bone Sarcoma

Active, not recruiting
1
40
US
Cyclophosphamide, Cytoxan®, Neosar®, attIL2-T cells
M.D. Anderson Cancer Center
Soft Tissue Sarcoma, Bone Sarcoma
09/25
09/25
SY-104 / Syena
NCT06066359: Phase I/II Trial of Cord Blood-Derived NK Cells Genetically Engineered With NY-ESO-1 TCR/IL-15 Cell Receptor for Relapsed/Refractory Multiple Myeloma

Recruiting
1/2
44
US
Fludarabine phosphate, Fludarabine, Fludara®, Cyclophosphamide, Cytoxan®, Neosar®, NY-ESO-1 TCR/IL-15 NK
M.D. Anderson Cancer Center
Myeloma
08/26
08/28
NCT06083883: Phase I/Ib Study of NK Expressing an Affinity-enhanced T-cell Receptor (TCR) Against the NY-ESO-1

Recruiting
1
44
US
Fludarabine phosphate, Fludarabine, Fludara®, NY-ESO-1 TCR/IL-15 NK, Cyclophosphamide, Cytoxan®, Neosar®
M.D. Anderson Cancer Center
Synovial Sarcoma, Myxoid/Round Cell Liposarcoma
11/26
11/28
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
CXCR2 and NGFR transduced TIL / UT MD Anderson Cancer Center
NCI-2014-02655, NCT01740557: Genetically Modified Therapeutic Autologous Lymphocytes Followed by Aldesleukin in Treating Patients With Stage III or Metastatic Melanoma

Completed
1/2
10
US
Aldesleukin, 125-L-Serine-2-133-interleukin 2, Proleukin, r-serHuIL-2, Recombinant Human IL-2, Recombinant Human Interleukin-2, CXCR2-transduced Autologous Tumor Infiltrating Lymphocytes, CXCR2-transduced Autologous TILs, Cyclophosphamide, (-)-Cyclophosphamide, 2H-1,3,2-Oxazaphosphorine, 2-[bis(2-chloroethyl)amino]tetrahydro-, 2-oxide, monohydrate, Carloxan, Ciclofosfamida, Ciclofosfamide, Cicloxal, Clafen, Claphene, CP monohydrate, CTX, CYCLO-cell, Cycloblastin, Cycloblastine, Cyclophospham, Cyclophosphamid monohydrate, Cyclophosphamidum, Cyclophosphan, Cyclophosphane, Cyclophosphanum, Cyclostin, Cyclostine, Cytophosphan, Cytophosphane, Cytoxan, Fosfaseron, Genoxal, Genuxal, Ledoxina, Mitoxan, Neosar, Revimmune, Syklofosfamid, WR- 138719, Fludarabine Phosphate, 2-F-ara-AMP, 9H-Purin-6-amine, 2-fluoro-9-(5-O-phosphono-.beta.-D-arabinofuranosyl)-, Beneflur, Fludara, SH T 586, Laboratory Biomarker Analysis, NGFR-transduced Autologous T Lymphocytes, Quality-of-Life Assessment, Quality of Life Assessment
M.D. Anderson Cancer Center, National Cancer Institute (NCI)
Metastatic Melanoma, Stage III Cutaneous Melanoma AJCC v7, Stage IV Cutaneous Melanoma AJCC v6 and v7
04/23
04/23
nelitolimod (SD-101) / TriSalus Life Sci, UT MD Anderson Cancer Center
NCT03007732: Pembrolizumab +/- SD-101 in Hormone-Naïve Oligometastatic Prostate Cancer With RT and iADT

Active, not recruiting
2
23
US
Pembrolizumab, MK-3475, Keytruda, SD-101, Toll-like receptor 9, Leuprolide acetate, Intermittent androgen deprivation therapy, Abiraterone Acetate, Prednisone, Stereotactic Body Radiation Therapy, SBRT
David Oh, Prostate Cancer Foundation, Merck Sharp & Dohme LLC, TriSalus Life Sciences, Inc.
Prostatic Neoplasms
08/25
08/25
I-SPY 2, NCT01042379: I-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast Cancer

Hourglass Jan 2023 - Dec 2023 : From P2 I-SPY 2 trial for invasive breast cancer
Checkmark Presentation of data from I-SPY trial for HR+/HER2- and TNBC breast cancer at SABCS 2022
Dec 2022 - Dec 2022: Presentation of data from I-SPY trial for HR+/HER2- and TNBC breast cancer at SABCS 2022
Checkmark Data from trial evaluating T-DM1+pertuzumab in the adjuvant setting
Nov 2018 - Nov 2018: Data from trial evaluating T-DM1+pertuzumab in the adjuvant setting
More
Recruiting
2
5000
US
Standard Therapy, Paclitaxel (Taxol); Doxorubicin (Adriamycin), AMG 386 with or without Trastuzumab, AMG 386 (Trebananib); (Trastuzumab) Herceptin, AMG 479 (Ganitumab) plus Metformin, Ganitumab, MK-2206 with or without Trastuzumab, (Trastuzumab) Herceptin, AMG 386 and Trastuzumab, AMG 386 (Trebananib); Trastuzumab (Herceptin), T-DM1 and Pertuzumab, T-DM1 (Trastuzumab emtansine); Pertuzumab (Perjeta), Pertuzumab and Trastuzumab, Pertuzumab (Perjeta); Trastuzumab (Herceptin), Ganetespib, ABT-888, Veliparib, Neratinib, PLX3397, Pembrolizumab - 4 cycle, Talazoparib plus Irinotecan, Patritumab and Trastuzumab, Pembrolizumab - 8 cycle, SGN-LIV1A, Durvalumab plus Olaparib, SD-101 + Pembrolizumab, Tucatinib plus trastuzumab and pertuzumab, Cemiplimab, Cemiplimab plus REGN3767, Trilaciclib with or without trastuzumab + pertuzumab, Trilaciclib (G1T28); Pertuzumab (Perjeta); Trastuzumab (Herceptin), SYD985 ([vic-]trastuzumab duocarmazine), Oral Paclitaxel + Encequidar + Dostarlimab (TSR-042) + Carboplatin with or without trastuzumab, Oral Paclitaxel + Encequidar (Oraxol); Dostarlimab (TSR-042); Trastuzumab (Herceptin), Oral Paclitaxel + Encequidar + Dostarlimab (TSR-042) with or without trastuzumab, Amcenestrant, SAR439859, Amcenestrant + Abemaciclib, Amcenestrant (SAR439859), Abemaciclib (Verzenio), Amcenestrant + Letrozole, Amcenestrant (SAR439859), Letrozole (Femara), ARX788, ARX788 + Cemiplimab, VV1 + Cemiplimab, VOYAGER V1™, VSV-IFNβ-NIS, Datopotamab deruxtecan, Dato-DXd, Datopotamab deruxtecan + Durvalumab, Zanidatamab, Lasofoxifene, Z-endoxifen, ARV-471, ARV-471 + Letrozole, ARV-471 + Abemaciclib, Endoxifen + Abemaciclib, Rilvegostomig + TDXd, Dan222 + Niraparib, Sarilumab + Cemiplimab + Paclitaxel
QuantumLeap Healthcare Collaborative
Breast Neoplasms, Breast Cancer, Breast Tumors, Angiosarcoma, TNBC - Triple-Negative Breast Cancer, HER2-positive Breast Cancer, HER2-negative Breast Cancer, Hormone Receptor Positive Tumor, Hormone Receptor Negative Tumor, Early-stage Breast Cancer, Locally Advanced Breast Cancer
12/30
12/31
NCT02927964: TLR9 Agonist SD-101, Ibrutinib, and Radiation Therapy in Treating Patients With Relapsed or Refractory Grade 1-3A Follicular Lymphoma

Completed
1/2
21
US
Ibrutinib, BTK Inhibitor PCI-32765, CRA-032765, PCI-32765, Radiation Therapy, Cancer Radiotherapy, Irradiate, Irradiated, Irradiation, RADIATION, Radiotherapeutics, Radiotherapy, RT, Therapy, Radiation, TLR9 Agonist SD-101, ISS-ODN SD-101, SD-101
Robert Lowsky, Janssen, LP, National Cancer Institute (NCI), The Leukemia and Lymphoma Society, Rising Tide Foundation
Grade 1 Follicular Lymphoma, Grade 2 Follicular Lymphoma, Grade 3a Follicular Lymphoma, Recurrent Follicular Lymphoma, Refractory Follicular Lymphoma, Mantle Cell Lymphoma, Marginal Zone Lymphoma
05/23
05/23
PERIO-02, NCT05220722: Pressure Enabled Delivery of SD-101 With Checkpoint Blockade for Primary Liver Tumors

Active, not recruiting
1/2
89
US
SD-101, Pembrolizumab, Keytruda, Nivolumab, Opdivo, Ipilimumab, Yervoy
TriSalus Life Sciences, Inc.
Hepatocellular Carcinoma, Intrahepatic Cholangiocarcinoma
12/23
01/25
NCT03831295: SD-101 and BMS-986178 in Treating Patients With Advanced or Metastatic Solid Malignancies

Completed
1
12
US
Anti-OX40 Antibody BMS 986178, BMS 986178, BMS-986178, TLR9 Agonist SD-101, ISS-ODN SD-101, SD-101
Ronald Levy, Bristol-Myers Squibb
Advanced Malignant Solid Neoplasm, Extracranial Solid Neoplasm, Metastatic Malignant Solid Neoplasm
10/21
10/21
NCT04050085: SD-101, Nivolumab, and Radiation Therapy in Treating Patients With Chemotherapy-Refractory Metastatic Pancreatic Cancer

Completed
1
6
US
Nivolumab, BMS-936558, MDX-1106, NIVO, ONO-4538, Opdivo, Radiation Therapy, Cancer Radiotherapy, Irradiate, Irradiated, irradiation, Radiation, Radiotherapeutics, RADIOTHERAPY, RT, Therapy, Radiation, TLR9 Agonist SD-101, ISS-ODN SD-101, SD-101
University of California, Davis, National Cancer Institute (NCI), Bristol-Myers Squibb, Dynavax Technologies Corporation
Metastatic Pancreatic Adenocarcinoma, Refractory Pancreatic Adenocarcinoma, Stage IV Pancreatic Cancer AJCC v8
12/21
05/22
NCT03410901: TLR9 Agonist SD-101, Anti-OX40 Antibody BMS 986178, and Radiation Therapy in Treating Patients With Low-Grade B-Cell Non-Hodgkin Lymphomas

Completed
1
14
US
Anti-OX40 Antibody BMS 986178, BMS 986178, BMS-986178, Laboratory Biomarker Analysis, Radiation Therapy, Cancer Radiotherapy, Irradiate, Irradiated, irradiation, RADIATION, Radiotherapeutics, radiotherapy, RT, Therapy, Radiation, TLR9 Agonist SD-101, ISS-ODN SD-101, SD-101
Ronald Levy, National Cancer Institute (NCI)
B-Cell Non-Hodgkin Lymphoma, Grade 1 Follicular Lymphoma, Grade 2 Follicular Lymphoma, Grade 3a Follicular Lymphoma, Lymphoplasmacytic Lymphoma, Mantle Cell Lymphoma, Marginal Zone Lymphoma, Small Lymphocytic Lymphoma
10/24
10/24
PERIO-01, NCT04935229: Intrahepatic Delivery of SD-101 by Pressure-Enabled Regional Immuno-oncology (PERIO), With Checkpoint Blockade in Adults With Metastatic Uveal Melanoma

Hourglass Jul 2024 - Dec 2024 : P1 data from PERIO-01 trial for uveal melanoma liver metastases
Active, not recruiting
1
80
US
SD-101, Nivolumab, Opdivo, Ipilimumab, Yervoy, Nivolumab and Relatlimab, Opdualag
TriSalus Life Sciences, Inc.
Metastatic Uveal Melanoma in the Liver
09/24
01/25
PERIO-03, NCT05607953: Pressure Enabled Intrapancreatic Delivery of SD-101 With Checkpoint Blockade for Locally Advanced Pancreatic Adenocarcinoma

Recruiting
1
60
US
SD-101, anti-PD-1
TriSalus Life Sciences, Inc.
Locally Advanced Pancreatic Adenocarcinoma
10/24
10/26
NCT06710223: Cryoablation and Arterial Infusion of SD-101 in Combination with Durvalumab and Tremelimumab

Recruiting
1
20
US
SD-101, nelitolimod, Cryotherapy, Tremelimumab, Durvalumab
University of California, San Diego, TriSalus Life Sciences
Hepatocellular Carcinoma
06/27
06/27
UCART123 / Cellectis
2018-001018-14: Study to evaluate the safety and efficacy of UCART123 in adults with high risk Acute Myeloid Leukaemia

Not yet recruiting
1/2
18
Europe
UCART123, Infusion
CELLECTIS SA, CELLECTIS SA
Adverse genetic Acute Myeloid Leukaemia, Blood Cancer, Diseases [C] - Cancer [C04]
 
 
AMELI-01, NCT03190278: Study Evaluating Safety and Efficacy of UCART123v1.2 in Patients With Relapsed/Refractory Acute Myeloid Leukemia

Hourglass Jan 2021 - Dec 2021 : Data from trial for r/r AML
Hourglass Jun 2021 - Jun 2021 : Mature data from trial for r/r AML at ASCO/EHA 2021
Checkmark Initiated AMELI-01 trial for r/r AML
Jan 2020 - Jan 2020: Initiated AMELI-01 trial for r/r AML
Recruiting
1
65
US
UCART123v1.2
Cellectis S.A.
Relapsed/Refractory Acute Myeloid Leukemia
12/24
12/24
UCART CS1 / Cellectis
MELANI-01, NCT04142619: Study Evaluating Safety and Efficacy of UCART Targeting CS1 in Patients With Relapsed/Refractory Multiple Myeloma

Terminated
1
11
US
UCARTCS1A
Cellectis S.A.
Relapsed/Refractory Multiple Myeloma
06/23
06/23
UCART22 / Cellectis
2020-004768-24: Study to evaluate the safety and efficacy of UCART22 in patients with Acute Lymphoblastic Leukaemia that have relapsed or not responded to other treatments

Not yet recruiting
1/2
83
Europe
UCART22, Infusion
CELLECTIS SA, CELLECTIS SA
Acute Lymphoblastic Leukaemia. Leucémie aiguë lymphoblastique., Blood Cancer. Leucemie., Diseases [C] - Cancer [C04]
 
 
BALLI-01, NCT04150497: Phase 1/2 Study of UCART22 in Patients With Relapsed or Refractory CD22+ B-cell Acute Lymphoblastic Leukemia

Recruiting
1/2
40
Europe, US
UCART22, CLLS52, Alemtuzumab
Cellectis S.A.
B-cell Acute Lymphoblastic Leukemia
01/26
01/26
ERAS-007 / Erasca
HERKULES-1, NCT04866134: A Study of ERAS-007 as Monotherapy or in Combination With ERAS-601 in Patients With Advanced or Metastatic Solid Tumors

Active, not recruiting
1/2
200
US
ERAS-007, ERAS-601
Erasca, Inc.
Advanced or Metastatic Solid Tumors
05/25
11/25
HERKULES-3, NCT05039177: A Study of ERAS-007 in Patients With Advanced Gastrointestinal Malignancies

Active, not recruiting
1/2
102
US
ERAS-007, Encorafenib, Braftovi, Cetuximab, Erbitux, Palbociclib, Ibrance
Erasca, Inc.
Metastatic Colorectal Cancer, Metastatic Pancreatic Ductal Adenocarcinoma
08/25
12/25
HERKULES-2, NCT04959981: A Study of Anti-Cancer Therapies Targeting the MAPK Pathway in Patients With Advanced NSCLC

Completed
1b
24
US
ERAS-007, ERAS-601, Osimertinib, Tagrisso, Sotorasib, Lumakras
Erasca, Inc.
Advanced Non-squamous Non-small-cell Lung Cancer
04/23
04/23
vibecotamab (XmAb14045) / Xencor
NCI-2022-02215, NCT05285813: A Phase II Study of Vibecotamab (XmAb14045) for MRD- Positive AML and MDS After Hypomethylating Agent Failure

Recruiting
2
42
US
Vibecotamab, XmAb14045, Dexamethasone, Decadron, Acetaminophen, Tylenol®, Dorcol®, Feverallâ"¢, Panadol®, APAP, N-Acetyl-P-Aminophenol, Paracetamol, Ofirmevâ"¢, Diphenhydramine, Benadryl®
M.D. Anderson Cancer Center
AML, MDS
12/26
12/26
MDA-TIL / Iovance Biotherap, UT MD Anderson Cancer Center
NCI-2018-01509, NCT03610490: Autologous Tumor Infiltrating Lymphocytes MDA-TIL in Treating Patients With Recurrent or Refractory Ovarian Cancer, Colorectal Cancer, or Pancreatic Ductal Adenocarcinoma

Terminated
2
60
US
Autologous Tumor Infiltrating Lymphocytes MDA-TIL, MDA Autologous TILs, MDA Autologous Tumor Infiltrating Lymphocytes, MDA-TILs, Cyclophosphamide, (-)-Cyclophosphamide, 2H-1,3,2-Oxazaphosphorine, 2-[bis(2-chloroethyl)amino]tetrahydro-, 2-oxide, monohydrate, Carloxan, Ciclofosfamida, Ciclofosfamide, Cicloxal, Clafen, Claphene, CP monohydrate, CTX, CYCLO-cell, Cycloblastin, Cycloblastine, Cyclophospham, Cyclophosphamid monohydrate, Cyclophosphamide Monohydrate, Cyclophosphamidum, Cyclophosphan, Cyclophosphane, Cyclophosphanum, Cyclostin, Cyclostine, Cytophosphan, Cytophosphane, Cytoxan, Fosfaseron, Genoxal, Genuxal, Ledoxina, Mitoxan, Neosar, Revimmune, Syklofosfamid, WR- 138719, Fludarabine, Fluradosa, Interleukin-2, Epidermal Thymocyte Activating Factor, ETAF, IL-2, IL2, IL2 Protein, Interleukin 2, Interleukin 2 Precursor, Interleukin II, Lymphocyte Mitogenic Factor, Mitogenic Factor, Ro-236019, T Cell Growth Factor, T-Cell Growth Factor, TCGF, Thymocyte Stimulating Factor, TSF, Quality-of-Life Assessment, Quality of Life Assessment
M.D. Anderson Cancer Center, Bristol-Myers Squibb, Iovance Biotherapeutics, National Cancer Institute (NCI)
Malignant Solid Neoplasm, Metastatic Colorectal Adenocarcinoma, Metastatic Ovarian Carcinoma, Metastatic Pancreatic Ductal Adenocarcinoma, Platinum-Resistant Ovarian Carcinoma, Recurrent High Grade Ovarian Serous Adenocarcinoma, Recurrent Ovarian Carcinosarcoma, Refractory Colorectal Carcinoma, Stage IV Colorectal Cancer AJCC v8, Stage IVA Colorectal Cancer AJCC v8, Stage IVB Colorectal Cancer AJCC v8, Stage IVC Colorectal Cancer AJCC v8
08/24
08/24
RPM CD19-mbIL15-CAR-T cells / Alaunos Therap, UT MD Anderson Cancer Center, Eden BioCell
ChiCTR2000034793: An Exploratory Clinical Study Evaluating the Safety and Efficacy of Anti-CD19 Autologous CAR T-cells Produced by Rapid Personalized Manufacture (RPM CD19-mbIL15-CAR-T Cell Infusion) in Patients With Relapsed/Refractory B-cell Malignancies

Not yet recruiting
N/A
12
 
RPM CD19-mbIL15-CAR-T cell infusion
Ningbo First Hospital; TriArm Therapeutics (Shanghai) Co., Ltd, TriArm Therapeutics (Shanghai) Co., Ltd
B cell malignancy
 
 
ChiCTR2100050678: An Exploratory Clinical Study Evaluating the Safety and Efficacy of Anti-CD19 Autologous CAR T-cells Produced by Rapid Personalized Manufacture (RPM CD19-mbIL15-CAR-T Cell Infusion) in Patients With Relapsed/Refractory B-cell Malignancies

Recruiting
N/A
12
 
Treat with RPM CD19-mbIL15-CAR-T cells
Tongji Hospital of Tongji University; TriArm Therapeutics (shanghai) Co., Ltd., TriArm Therapeutics (Shanghai) Co., Ltd
B cell malignancy
 
 
NTRX-07 / NeuroTherapia
NCT06194552: A Multiple Dose Study of the Safety and Pharmacokinetics of NTRX-07

Completed
1
32
Europe, US
NTRX-07, MDA7, Placebo
NeuroTherapia, Inc., CRU Early Phase Unit Kistarcsa
Alzheimer Disease
05/23
06/23
KA2507 / Karus Therap, UT MD Anderson Cancer Center
2019-001459-38: Finding the tolerable recommended dose of KA2507 and how effective it is at treating patient with advance biliary tract cancer who have previously been treated with standard of care chemotherapy

Not yet recruiting
2
40
Europe
KA2507, N/A, Capsule, hard
Karus Therapeutics Limited
Advanced Biliary Tract Cancer, Advanced Biliary Tract cancer, Diseases [C] - Cancer [C04]
 
 
JIN-001 / J Ints Bio
MPT0B64, NCT04294875: Phase I, FIH, MTD for 0, Multi-centre, Open-label, Subject With Locally Advanced or Metastatic Solid Malignancies

Withdrawn
1
15
NA
MPT0B640
J Ints Bio
Advanced Solid Tumor, Metastatic Solid Tumor
11/27
11/27
IPN60090 / UT MD Anderson Cancer Center, Ipsen
NCT05039801: IACS-6274 With or Without Bevacizumab and Paclitaxel for the Treatment of Advanced Solid Tumors

Recruiting
1
54
US
Bevacizumab, ABP 215, Anti-VEGF, Anti-VEGF Humanized Monoclonal Antibody, Anti-VEGF Monoclonal Antibody SIBP04, Anti-VEGF rhuMAb, Avastin, Bevacizumab awwb, Bevacizumab Biosimilar ABP 215, Bevacizumab Biosimilar BEVZ92, Bevacizumab Biosimilar BI 695502, Bevacizumab Biosimilar CBT 124, Bevacizumab Biosimilar CT-P16, Bevacizumab Biosimilar FKB238, Bevacizumab Biosimilar GB-222, Bevacizumab Biosimilar HD204, Bevacizumab Biosimilar HLX04, Bevacizumab Biosimilar IBI305, Bevacizumab Biosimilar LY01008, Bevacizumab Biosimilar MIL60, Bevacizumab Biosimilar Mvasi, Bevacizumab Biosimilar MYL-1402O, Bevacizumab Biosimilar QL 1101, Bevacizumab Biosimilar QL1101, Bevacizumab Biosimilar RPH-001, Bevacizumab Biosimilar SCT501, Bevacizumab Biosimilar Zirabev, Bevacizumab-awwb, Bevacizumab-bvzr, BP102, BP102 Biosimilar, HD204, Immunoglobulin G1 (Human-Mouse Monoclonal rhuMab-VEGF Gamma-Chain Anti-Human Vascular Endothelial Growth Factor), Disulfide With Human-Mouse Monoclonal rhuMab-VEGF Light Chain, Dimer, Mvasi, MYL-1402O, QL1101, Recombinant Humanized Anti-VEGF Monoclonal Antibody, rhuMab-VEGF, SCT501, SIBP 04, SIBP-04, SIBP04, Zirabev, Glutaminase-1 Inhibitor IACS-6274, GLS1 Inhibitor IACS-6274, IACS 6274, IACS-6274, IACS6274, IPN 60090, IPN-60090, IPN60090, Paclitaxel, Anzatax, Asotax, Bristaxol, Praxel, Taxol, Taxol Konzentrat, Capivasertib, AZD5363
M.D. Anderson Cancer Center
Advanced Endometrial Carcinoma, Advanced Head and Neck Squamous Cell Carcinoma, Advanced Malignant Solid Neoplasm, Advanced Melanoma, Advanced Ovarian Clear Cell Adenocarcinoma, Chondrosarcoma, Clinical Stage III Cutaneous Melanoma AJCC v8, Clinical Stage IV Cutaneous Melanoma AJCC v8, Pathologic Stage III Cutaneous Melanoma AJCC v8, Pathologic Stage IIIA Cutaneous Melanoma AJCC v8, Pathologic Stage IIIB Cutaneous Melanoma AJCC v8, Pathologic Stage IIIC Cutaneous Melanoma AJCC v8, Pathologic Stage IIID Cutaneous Melanoma AJCC v8, Pathologic Stage IV Cutaneous Melanoma AJCC v8, Recurrent Ovarian High Grade Serous Adenocarcinoma, Refractory Endometrial Carcinoma, Refractory Head and Neck Squamous Cell Carcinoma, Refractory Melanoma, Refractory Ovarian Clear Cell Adenocarcinoma, Refractory Ovarian High Grade Serous Adenocarcinoma, Stage III Ovarian Cancer AJCC v8, Stage III Uterine Corpus Cancer AJCC v8, Stage IIIA Ovarian Cancer AJCC v8, Stage IIIA Uterine Corpus Cancer AJCC v8, Stage IIIA1 Ovarian Cancer AJCC v8, Stage IIIA2 Ovarian Cancer AJCC v8, Stage IIIB Ovarian Cancer AJCC v8, Stage IIIB Uterine Corpus Cancer AJCC v8, Stage IIIC Ovarian Cancer AJCC v8, Stage IIIC Uterine Corpus Cancer AJCC v8, Stage IIIC1 Uterine Corpus Cancer AJCC v8, Stage IIIC2 Uterine Corpus Cancer AJCC v8, Stage IV Ovarian Cancer AJCC v8, Stage IV Uterine Corpus Cancer AJCC v8, Stage IVA Ovarian Cancer AJCC v8, Stage IVA Uterine Corpus Cancer AJCC v8, Stage IVB Ovarian Cancer AJCC v8, Stage IVB Uterine Corpus Cancer AJCC v8
05/26
05/26
TAK-007 / Takeda, UT MD Anderson Cancer Center
TAK-007-2001, NCT05020015: A Study of TAK-007 in Adults With Relapsed or Refractory (r/r) B-cell Non-Hodgkin Lymphoma (NHL)

Active, not recruiting
2
27
US
TAK-007, Chemotherapy Agents
Takeda
Relapsed or Refractory (r/r) B-cell Non-Hodgkin Lymphoma (NHL)
10/25
06/30
NCT06377228: A Study of TAK-007 in Adults With Refractory Lupus Nephritis (LN)

Not yet recruiting
1
20
NA
TAK-007, Chemotherapy Agents
Takeda
Refractory Lupus Nephritis
04/29
04/29
OBX-115 / Obsidian, UT MD Anderson Cancer Center
Agni-01, NCT06060613: Safety and Efficacy of OBX-115 in Advanced Solid Tumors

Recruiting
1/2
52
US
OBX-115
Obsidian Therapeutics, Inc.
Tumor Skin, Metastatic Melanoma, Melanoma, Lung Cancer, Metastatic Lung Cancer, Non Small Cell Lung Cancer, Metastatic Non Small Cell Lung Cancer
10/25
10/27
NCT05470283: Phase I, Open-Label, Study of Tumor Infiltrating Lymphocytes Engineered With Membrane Bound IL15 Plus Acetazolamide in Adult Patients With Metastatic Melanoma

Active, not recruiting
1
21
US
OBX-115, Acetazolamide, Cyclophosphamide, Cytoxan®, Neosar, Furosemide, Mesna, Fludarabine Phosphate, Fludarabine, Fludara
M.D. Anderson Cancer Center
Tumor, Metastatic Melanoma, Melanoma
04/27
04/27
ERAS-601 / Erasca
FLAGSHP-1, NCT04670679: A Dose Escalation/Expansion Study of ERAS-601 in Patients With Advanced or Metastatic Solid Tumors

Active, not recruiting
1
200
US, RoW
ERAS-601, Cetuximab, Erbitux, Pembrolizumab, Keytruda
Erasca, Inc.
Advanced or Metastatic Solid Tumors
11/25
02/26
BLU-222 / Blueprint Medicines
VELA, NCT05252416: () Study of BLU-222 in Advanced Solid Tumors

Hourglass Jan 2023 - Jun 2023 : Anticipated results from VELA study for BLU-222 in CDK2-vulnerable cancers
Hourglass Jan 2023 - Jun 2023 : Initial clinical data from VELA trial in CDK2-vulnerable cancers
Hourglass Jun 2023 - Jun 2023 : Safety and efficacy data from VELA trial in breast cancer and other cancers vulnerable to CDK2 inhibition
Active, not recruiting
1/2
366
Europe, US
BLU-222, Carboplatin, Ribociclib, Fulvestrant
Blueprint Medicines Corporation
Advanced Solid Tumors, HR+ Breast Cancer, CCNE1 Amplification, HER2-negative Breast Cancer, Ovarian Cancer, Endometrial Cancer, Gastric Cancer, Esophageal Adenocarcinoma, Carcinosarcoma
11/25
09/26
CB-NK-TGF-βR2-/NR3C1 / UT MD Anderson Cancer Center
NCT05040568: A PHASE IB STUDY OF IMMUNOTHERAPY WITH EX VIVO PRE-ACTIVATED AND EXPANDED CB-NK CELLS IN COMBINATION WITH CETUXIMAB, IN COLORECTAL CANCER PATIENTS WITH MINIMAL RESIDUAL DISEASE (MRD)

Active, not recruiting
1
15
US
Cetuximab, C225, Erbituxâ"¢, IMC-C225, MOAB C225, Expanded CB-NK cells, Fludarabine phosphate, Fludarabine, Fludara®, Cyclophosphamide, Cytoxan®, Neosar®
M.D. Anderson Cancer Center
Colon Cancer, Resected Stage
02/27
02/27
Undisclosed MSC-derived Exosomes with KrasG12D siRNA / UT MD Anderson Cancer Center
iEXPLORE, NCT03608631: IExosomes in Treating Participants with Metastatic Pancreas Cancer with KrasG12D Mutation

Active, not recruiting
1
15
US
Mesenchymal Stromal Cells-derived Exosomes with KRAS G12D siRNA, MSC-derived Exosomes with KrasG12D siRNA (SY); KrasG12D siRNA-loaded Mesenchymal Stromal Cells-derived Exosomes (SY)
M.D. Anderson Cancer Center
KRAS NP_004976.2:p.G12D, Metastatic Pancreatic Adenocarcinoma, Pancreatic Ductal Adenocarcinoma, Stage IV Pancreatic Cancer AJCC V8
04/25
04/25
CAR.70/IL15-transduced CB-NK cells / UT MD Anderson Cancer Center
NCT05703854: Study of CAR.70-engineered IL15-transduced Cord Blood-derived NK Cells in Conjunction With Lymphodepleting Chemotherapy for the Management of Advanced Renal Cell Carcinoma, Mesothelioma and Osteosarcoma

Recruiting
1/2
50
US
CAR.70/IL15-transduced CB-derived NK cells, Fludarabine phosphate, Fludarabine, Fludara®, Cyclophosphamide, Cytoxan®, Neosar®
M.D. Anderson Cancer Center
Advanced Renal Cell Carcinoma, Advanced Mesothelioma, Advanced Osteosarcoma
09/25
09/27
NCT05092451: Phase I/II Study of CAR.70- Engineered IL15-transduced Cord Blood-derived NK Cells in Conjunction With Lymphodepleting Chemotherapy for the Management of Relapse/Refractory Hematological Malignances

Recruiting
1/2
80
US
Cyclophosphamide, Cytoxan®, Neosar®, CAR.70/IL15-transduced CB-NK cells, Fludarabine phosphate, Fludarabine, Fludara®
M.D. Anderson Cancer Center
B-Cell Lymphoma, Myelodysplastic Syndromes (MDS), Acute Myeloid Leukemia (AML), Multiple Myeloma, Plasma Cell Leukemia, Hodgkin Lymphoma, T-cell Non-Hodgkin's Lymphoma/ T-cell Acute Lymphoblastic Leukmeia, Myelodysplastic Syndrome / Chronic Myelomonocytic Leukemia, Blastic Transformation of Chronic Myeloid Leukemia, Germ Cell Tumors
08/26
08/26
attIL2-T / UT MD Anderson Cancer Center
NCT05621668: A First-In-Human Phase 1 Trial of T-Cell Membrane-Anchored Tumor Targeted Il12 (Attil12)- T-Cell Therapy in Subjects With Advanced/Metastatic Soft Tissue and Bone Sarcoma

Active, not recruiting
1
40
US
Cyclophosphamide, Cytoxan®, Neosar®, attIL2-T cells
M.D. Anderson Cancer Center
Soft Tissue Sarcoma, Bone Sarcoma
09/25
09/25
SY-104 / Syena
NCT06066359: Phase I/II Trial of Cord Blood-Derived NK Cells Genetically Engineered With NY-ESO-1 TCR/IL-15 Cell Receptor for Relapsed/Refractory Multiple Myeloma

Recruiting
1/2
44
US
Fludarabine phosphate, Fludarabine, Fludara®, Cyclophosphamide, Cytoxan®, Neosar®, NY-ESO-1 TCR/IL-15 NK
M.D. Anderson Cancer Center
Myeloma
08/26
08/28
NCT06083883: Phase I/Ib Study of NK Expressing an Affinity-enhanced T-cell Receptor (TCR) Against the NY-ESO-1

Recruiting
1
44
US
Fludarabine phosphate, Fludarabine, Fludara®, NY-ESO-1 TCR/IL-15 NK, Cyclophosphamide, Cytoxan®, Neosar®
M.D. Anderson Cancer Center
Synovial Sarcoma, Myxoid/Round Cell Liposarcoma
11/26
11/28

Download Options